Orna Therapeutics, Inc. is a biotechnology company developing medicines based on engineered circular RNA. The company designs and manufactures circular RNA constructs and lipid nanoparticle delivery systems to drive durable in vivo expression of therapeutic proteins.
Orna’s platform is applied to genetic medicines and cell engineering, including programs that aim to generate CAR-T cells inside the patient and other applications across immunology and oncology. Its work spans discovery through early clinical development, with an emphasis on scalable RNA and nanoparticle formulation capabilities to enable systemic delivery and targeted activity.
None yet. When a new project in the record names Orna Therapeutics as owner, partner or investor, it shows here.
Revenue rose 48% to $23.0bn driven by Mounjaro and Zepbound; updated 2026 revenue guidance to $85–87bn; retatrutide Phase 3 package complete supporting a Q1 2027 BLA.
EPS jumped ~170% reported (~156% non‑GAAP); volume growth offset lower realized prices; FDA approved oral GLP‑1 Foundayo; positive Phase‑3 readouts; four acquisitions announced
Lilly acquires Orna to enhance genetic medicine and in vivo cell engineering, focusing on autoimmune diseases with circular RNA and lipid nanoparticle technology.
